<< Read Full Article
<< Read Full Article
Shares in BioCryst (BCRX Quote) jumped in premarket trading Tuesday after regulators granted orphan status to the company's lead anticancer drug, forodesine hydrochloride, boosting the Alabama-based biotech's prospects.
The company is currently developing forodesine hydrochloride for the treatment of T-cell mediated cancers. BioCryst also has a phase 2a clinical trial for T-cell leukemia under way.
The two additional indications are for treatment of chronic lymphocytic leukemia and related leukemias as well as acute lymphoblastic leukemia. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet